Literature DB >> 8596487

Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas.

S Fujitani1, T Ikenoue, M Akiyoshi, T Maki, T Yada.   

Abstract

N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) is a nonsulfonylurea hypoglycemic agent that decreases blood glucose levels in nondiabetic and diabetic animals. In the present study, we attempted to determine the effect of A-4166 on hormone secretion from the in vitro-perfused rat pancreas and to examine the underlying secretory mechanisms. In the presence of basal glucose (3 mmol/L), A-4166 markedly stimulated insulin and somatostatin release in a concentration-dependent manner over 0.03 to 3 mmol/L. A sulfonylurea, tolbutamide, also stimulated insulin and somatostatin release. A-4166 and tolbutamide elevated the level of glucagon release; however, the change lacked a clear concentration-dependent property. A-4166 at 0.3 mmol/L and tolbutamide at 3 mmol/L exhibited maximal stimulation of insulin release to a similar extent, indicating that A-4166 is one log-order more potent than and as effective as tolbutamide. By contrast, A-4166 stimulated somatostatin release to a threefold greater extent than tolbutamide. A-4166 evoked an increase in the cytosolic free-Ca2+ concentration ([Ca2+]i) in rat pancreatic beta cells. [Ca2+]i and insulin secretory responses to A-4166 were inhibited by nitrendipine (NTD), a blocker of the L-type Ca2+ channel, and by diazoxide (DAZ), an opener of the adenosine triphosphate (ATP)-sensitive K+ channel. Furthermore, A-4166-stimulated somatostatin release was also inhibited by NTD and by DAZ. The results indicate that A-4166 and tolbutamide stimulate the release of insulin and somatostatin, and that A-4166 is much more effective than tolbutamide in releasing somatostatin, a hormone that attenuates hyperglycemia under certain circumstances. It is concluded that A-4166-induced insulin release is mediated by an increase in [Ca2+]i in beta cells. An inhibition of ATP-sensitive K+ channels and a consequent activation of L-type Ca2+ channels appear to play a key role not only in insulin secretion from beta cells, but also in somatostatin secretion from delta cells in response to A-4166.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8596487     DOI: 10.1016/s0026-0495(96)90051-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  Different metabolic responses in alpha-, beta-, and delta-cells of the islet of Langerhans monitored by redox confocal microscopy.

Authors:  Ivan Quesada; Mariana G Todorova; Bernat Soria
Journal:  Biophys J       Date:  2006-01-06       Impact factor: 4.033

2.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

3.  Stimulation of insulin and somatostatin release by two meglitinide analogs.

Authors:  V Leclercq-Meyer; L Ladrière; J Fuhlendorff; W J Malaisse
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

4.  Models of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

Review 5.  Meglitinide analogues in the treatment of type 2 diabetes mellitus.

Authors:  R Landgraf
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

6.  JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats.

Authors:  T Ohta; N Furukawa; G Komuro; F Yonemori; K Wakitani
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

Review 7.  Nateglinide.

Authors:  C J Dunn; D Faulds
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

8.  Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Authors:  Leon S Farhy; Zhongmin Du; Qiang Zeng; Paula P Veldhuis; Michael L Johnson; Kenneth L Brayman; Anthony L McCall
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-06-24       Impact factor: 4.310

9.  Pancreatic network control of glucagon secretion and counterregulation.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

10.  Anti-diabetic effect of Wen-pi-tang-Hab-Wu-ling-san extract in streptozotocin-induced diabetic rats.

Authors:  Hyo Won Jung; Jin Ki Jung; Mahesh Ramalingam; Cheol-Ho Yoon; Hyo Sang Bae; Yong-Ki Park
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.